Aligos Therapeutics, Inc. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
Aligos Therapeutics, Inc. (ALGS) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-03-05
- Aligos Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00.
- Aligos Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $0.00.
- Aligos Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- Aligos Therapeutics, Inc. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-10 |
| 2022-12-31 | $0.00 10-K · filed 2024-03-12 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-10 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |